PT3656384T - Combinações que compreendem derivados de 5-fenoxi-3hpirimidin- 4-ona e a sua utilização para a profilaxia ou tratamento de infeção por vih - Google Patents
Combinações que compreendem derivados de 5-fenoxi-3hpirimidin- 4-ona e a sua utilização para a profilaxia ou tratamento de infeção por vihInfo
- Publication number
- PT3656384T PT3656384T PT192101673T PT19210167T PT3656384T PT 3656384 T PT3656384 T PT 3656384T PT 192101673 T PT192101673 T PT 192101673T PT 19210167 T PT19210167 T PT 19210167T PT 3656384 T PT3656384 T PT 3656384T
- Authority
- PT
- Portugal
- Prior art keywords
- pyrimidin
- prophylaxis
- hiv
- phenoxy
- infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012001358 | 2012-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3656384T true PT3656384T (pt) | 2022-03-22 |
Family
ID=49354986
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137767026T PT2903977T (pt) | 2012-10-08 | 2013-10-07 | Derivados de 5-fenoxi-3h-pirimidin-4-ona e suas utilização como inibidores da transcriptase reversa de vih |
| PT192101673T PT3656384T (pt) | 2012-10-08 | 2013-10-07 | Combinações que compreendem derivados de 5-fenoxi-3hpirimidin- 4-ona e a sua utilização para a profilaxia ou tratamento de infeção por vih |
| PT171913072T PT3295942T (pt) | 2012-10-08 | 2013-10-07 | Combinações que compreendem derivados de 5-fenoxi-3h-pirimidin-4-ona e a sua utilização para a profilaxia ou tratamento de infeção por vih |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137767026T PT2903977T (pt) | 2012-10-08 | 2013-10-07 | Derivados de 5-fenoxi-3h-pirimidin-4-ona e suas utilização como inibidores da transcriptase reversa de vih |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT171913072T PT3295942T (pt) | 2012-10-08 | 2013-10-07 | Combinações que compreendem derivados de 5-fenoxi-3h-pirimidin-4-ona e a sua utilização para a profilaxia ou tratamento de infeção por vih |
Country Status (47)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012048113A2 (en) | 2010-10-07 | 2012-04-12 | The General Hospital Corporation | Biomarkers of cancer |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| UY35735A (es) | 2013-09-16 | 2015-04-30 | Bayer Pharma AG | Trifluorometilpirimidinonas disustituidas y su uso |
| DK3125894T3 (da) * | 2014-04-01 | 2020-11-16 | Merck Sharp & Dohme | Prodrugs af hiv-reverstranscriptasehæmmere |
| AU2015308350B2 (en) | 2014-08-29 | 2020-03-05 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| FR3027901B1 (fr) * | 2014-10-31 | 2018-03-16 | Universite De Reims Champagne Ardenne | Nouveaux procedes appartenant a la famille des pyridazinones. |
| US10350165B2 (en) * | 2014-12-12 | 2019-07-16 | Ojai Energetics Pbc | Methods and systems for forming stable droplets |
| JP7067793B2 (ja) | 2015-10-23 | 2022-05-16 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基編集因子およびその使用 |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
| KR20190130613A (ko) | 2017-03-23 | 2019-11-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物 |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CA3075727A1 (en) * | 2017-09-18 | 2019-03-21 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
| WO2019157087A1 (en) | 2018-02-06 | 2019-08-15 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
| SG11202010183XA (en) | 2018-04-30 | 2020-11-27 | Ribon Therapeutics Inc | Pyridazinones as parp7 inhibitors |
| TWI828758B (zh) | 2018-09-18 | 2024-01-11 | 美商金翅雀生技公司 | 噠嗪酮及其使用方法 |
| CN113423695A (zh) * | 2018-12-18 | 2021-09-21 | 默沙东公司 | 作为针对hiv感染细胞的选择性细胞毒剂的嘧啶酮衍生物 |
| EP3942040A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| JP2022533681A (ja) * | 2019-05-22 | 2022-07-25 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｈｉｖに感染した細胞に対する選択的細胞毒性薬としてのピリジノン誘導体 |
| KR20220079907A (ko) * | 2019-10-04 | 2022-06-14 | 골드핀치 바이오 인코포레이티드 | 국소분절사구체경화증 및 당뇨병성 신장 질환의 바이오마커 기반 치료 |
| MX2022005216A (es) | 2019-10-30 | 2022-06-02 | Ribon Therapeutics Inc | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). |
| JPWO2021107066A1 (pt) | 2019-11-28 | 2021-06-03 | ||
| TW202146416A (zh) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| AU2021350835A1 (en) | 2020-09-24 | 2023-04-27 | President And Fellows Of Harvard College | Prime editing guide rnas, compositions thereof, and methods of using the same |
| JP2024503437A (ja) | 2021-01-11 | 2024-01-25 | ザ ブロード インスティテュート，インコーポレーテッド | プライム編集効率及び精度を向上させるためのプライム編集因子バリアント、構築物、及び方法 |
| EP4363418A1 (en) * | 2021-07-01 | 2024-05-08 | JANSSEN Pharmaceutica NV | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
| CA3227004A1 (en) | 2021-08-06 | 2023-02-09 | The Broad Institute, Inc. | Improved prime editors and methods of use |
| WO2023076898A1 (en) | 2021-10-25 | 2023-05-04 | The Broad Institute, Inc. | Methods and compositions for editing a genome with prime editing and a recombinase |
| WO2023102538A1 (en) | 2021-12-03 | 2023-06-08 | The Broad Institute, Inc. | Self-assembling virus-like particles for delivery of prime editors and methods of making and using same |
| WO2023205687A1 (en) | 2022-04-20 | 2023-10-26 | The Broad Institute, Inc. | Improved prime editing methods and compositions |
| WO2023240137A1 (en) | 2022-06-08 | 2023-12-14 | The Board Institute, Inc. | Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing |
| WO2024077267A1 (en) | 2022-10-07 | 2024-04-11 | The Broad Institute, Inc. | Prime editing methods and compositions for treating triplet repeat disorders |
| WO2024108092A1 (en) | 2022-11-17 | 2024-05-23 | The Broad Institute, Inc. | Prime editor delivery by aav |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5519021A (en) | 1992-08-07 | 1996-05-21 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| AU4137899A (en) | 1998-04-27 | 1999-11-16 | Centre National De La Recherche Scientifique | 3-(amino-or aminoalkyl)pyridinone derivatives and their use for the treatment of HIV related diseases |
| IT1305313B1 (it) | 1998-07-17 | 2001-05-04 | Colla Paolo | 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1. |
| SE9904045D0 (sv) | 1999-11-09 | 1999-11-09 | Astra Ab | Compounds |
| MXPA03002299A (es) | 2000-09-15 | 2003-06-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de proteina cinasa. |
| KR20110132482A (ko) | 2003-02-07 | 2011-12-07 | 얀센 파마슈티카 엔.브이. | Ｈｉｖ 감염 예방용 피리미딘 유도체 |
| TW200423930A (en) | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| AU2004224191A1 (en) * | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
| JP2007517900A (ja) | 2004-01-12 | 2007-07-05 | ギリアード サイエンシーズ， インコーポレイテッド | ピリミジンホスホネート抗ウイルス化合物および使用方法 |
| EP1730120A1 (en) | 2004-03-23 | 2006-12-13 | F.Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| JP4810529B2 (ja) | 2004-04-23 | 2011-11-09 | エフ．ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素インヒビター |
| US7166738B2 (en) | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
| WO2006067587A2 (en) | 2004-12-22 | 2006-06-29 | Pfizer Limited | Nonnucleoside inhibitors of hiv-1 reverse transcriptase |
| AR057455A1 (es) | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| EP1940782B1 (en) | 2005-10-19 | 2009-03-11 | F.Hoffmann-La Roche Ag | N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors |
| JP2009515826A (ja) | 2005-10-19 | 2009-04-16 | エフ．ホフマン−ラ ロシュ アーゲー | フェニル−アセトアミドｎｎｒｔ阻害剤 |
| MX2009005449A (es) | 2006-11-24 | 2009-06-02 | Takeda Pharmaceutical | Compuesto heteromonociclico y uso del mismo. |
| US7803940B2 (en) | 2006-11-24 | 2010-09-28 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases |
| TW200831085A (en) | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
| BRPI0820162A2 (pt) * | 2007-11-20 | 2019-09-24 | Merck Sharp & Dohme | composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids |
| CN103254138A (zh) * | 2008-01-08 | 2013-08-21 | 默沙东公司 | 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法 |
| PL2552902T3 (pl) | 2010-03-30 | 2015-10-30 | Merck Canada Inc | Nienukleozydowe inhibitory odwrotnej transkryptazy |
| WO2011126969A1 (en) | 2010-04-08 | 2011-10-13 | Merck Sharp & Dohme Corp. | Prodrugs of an hiv reverse transcriptase inhibitor |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| DK3125894T3 (da) | 2014-04-01 | 2020-11-16 | Merck Sharp & Dohme | Prodrugs af hiv-reverstranscriptasehæmmere |
-
2013
- 2013-09-29 JO JOP/2013/0284A patent/JO3470B1/ar active
- 2013-10-02 AR ARP130103568A patent/AR092876A1/es active IP Right Grant
- 2013-10-07 ES ES13776702.6T patent/ES2645638T3/es active Active
- 2013-10-07 BR BR112015007742A patent/BR112015007742B8/pt active IP Right Grant
- 2013-10-07 AU AU2013329552A patent/AU2013329552B8/en active Active
- 2013-10-07 NO NO13776702A patent/NO2903977T3/no unknown
- 2013-10-07 PL PL19210167T patent/PL3656384T3/pl unknown
- 2013-10-07 SI SI201330835T patent/SI2903977T1/sl unknown
- 2013-10-07 PE PE2015001782A patent/PE20151787A1/es active IP Right Grant
- 2013-10-07 RS RS20220359A patent/RS63112B1/sr unknown
- 2013-10-07 PT PT137767026T patent/PT2903977T/pt unknown
- 2013-10-07 MX MX2015004448A patent/MX355040B/es active IP Right Grant
- 2013-10-07 ES ES19210167T patent/ES2909190T3/es active Active
- 2013-10-07 HU HUE13776702A patent/HUE037231T2/hu unknown
- 2013-10-07 SI SI201331662T patent/SI3295942T1/sl unknown
- 2013-10-07 US US14/047,515 patent/US9469634B2/en active Active
- 2013-10-07 PT PT192101673T patent/PT3656384T/pt unknown
- 2013-10-07 CN CN201380061513.7A patent/CN104822670B/zh active Active
- 2013-10-07 PL PL17191307T patent/PL3295942T3/pl unknown
- 2013-10-07 EP EP13776702.6A patent/EP2903977B1/en active Active
- 2013-10-07 KR KR1020157011661A patent/KR101696128B1/ko active IP Right Grant
- 2013-10-07 AP AP2015008355A patent/AP2015008355A0/xx unknown
- 2013-10-07 ES ES17191307T patent/ES2770774T3/es active Active
- 2013-10-07 DK DK17191307.2T patent/DK3295942T3/da active
- 2013-10-07 EP EP19210167.3A patent/EP3656384B1/en active Active
- 2013-10-07 HR HRP20220502TT patent/HRP20220502T1/hr unknown
- 2013-10-07 TW TW105108710A patent/TWI598343B/zh active
- 2013-10-07 WO PCT/US2013/063612 patent/WO2014058747A1/en active Application Filing
- 2013-10-07 ME MEP-2017-264A patent/ME02918B/me unknown
- 2013-10-07 GE GEAP201313818A patent/GEP20186838B/en unknown
- 2013-10-07 CA CA2887312A patent/CA2887312C/en active Active
- 2013-10-07 RS RS20200052A patent/RS59863B1/sr unknown
- 2013-10-07 PL PL13776702T patent/PL2903977T3/pl unknown
- 2013-10-07 LT LTEP19210167.3T patent/LT3656384T/lt unknown
- 2013-10-07 JP JP2015535852A patent/JP5877281B2/ja active Active
- 2013-10-07 EP EP17191307.2A patent/EP3295942B1/en active Active
- 2013-10-07 RS RS20171164A patent/RS56543B1/sr unknown
- 2013-10-07 SI SI201331974T patent/SI3656384T1/sl unknown
- 2013-10-07 LT LTEP13776702.6T patent/LT2903977T/lt unknown
- 2013-10-07 DK DK13776702.6T patent/DK2903977T3/en active
- 2013-10-07 MD MD20150047A patent/MD4625C1/ro active IP Right Grant
- 2013-10-07 MA MA37959A patent/MA37959A2/fr unknown
- 2013-10-07 DK DK19210167.3T patent/DK3656384T3/da active
- 2013-10-07 EA EA201590674A patent/EA033436B1/ru not_active IP Right Cessation
- 2013-10-07 HU HUE17191307A patent/HUE048670T2/hu unknown
- 2013-10-07 PT PT171913072T patent/PT3295942T/pt unknown
- 2013-10-07 TW TW102136225A patent/TWI538907B/zh active
- 2013-10-07 HU HUE19210167A patent/HUE058903T2/hu unknown
- 2013-10-07 LT LTEP17191307.2T patent/LT3295942T/lt unknown
- 2013-10-07 SG SG11201502620UA patent/SG11201502620UA/en unknown
- 2013-10-07 NZ NZ706729A patent/NZ706729A/en unknown
- 2013-10-07 MY MYPI2015000836A patent/MY192716A/en unknown
- 2013-10-07 UA UAA201504486A patent/UA114006C2/uk unknown
-
2015
- 2015-03-23 TN TNP2015000106A patent/TN2015000106A1/fr unknown
- 2015-04-01 IL IL238090A patent/IL238090B/en active IP Right Grant
- 2015-04-06 PH PH12015500764A patent/PH12015500764B1/en unknown
- 2015-04-07 NI NI201500048A patent/NI201500048A/es unknown
- 2015-04-08 GT GT201500088A patent/GT201500088A/es unknown
- 2015-04-08 CR CR20150183A patent/CR20150183A/es unknown
- 2015-04-08 DO DO2015000082A patent/DOP2015000082A/es unknown
- 2015-04-08 CO CO15077967A patent/CO7350655A2/es unknown
- 2015-04-08 CL CL2015000880A patent/CL2015000880A1/es unknown
- 2015-05-07 ZA ZA2015/03143A patent/ZA201503143B/en unknown
- 2015-05-12 EC ECIEPI201518618A patent/ECSP15018618A/es unknown
- 2015-08-18 HK HK15107948.1A patent/HK1207369A1/xx unknown
-
2016
- 2016-01-25 JP JP2016011415A patent/JP6097422B2/ja active Active
- 2016-02-01 US US15/012,445 patent/US9718819B2/en active Active
-
2017
- 2017-06-07 US US15/616,756 patent/US10189831B2/en active Active
- 2017-11-20 CY CY20171101214T patent/CY1119655T1/el unknown
- 2017-11-22 HR HRP20171819TT patent/HRP20171819T1/hr unknown
-
2018
- 2018-09-20 HK HK18112148.6A patent/HK1252786A1/zh unknown
-
2020
- 2020-01-30 HR HRP20200158TT patent/HRP20200158T1/hr unknown
- 2020-02-04 CY CY20201100097T patent/CY1122585T1/el unknown
-
2022
- 2022-03-30 CY CY20221100247T patent/CY1125202T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1252786A1 (zh) | 包含5-苯氧基-3h-嘧啶-4-酮衍生物的組合物及其用於預防或治療hiv感染的方法 | |
| HK1246296A1 (zh) | 多環氨基甲酰基吡啶酮化合物和其用於治療hiv感染的用途 | |
| HK1246295A1 (zh) | 多環氨基甲酰基吡啶酮化合物和其用於治療hiv感染的用途 | |
| ZA201500921B (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases | |
| IL244220A0 (en) | Methods and preparations for RNA-guided treatment of HIV infection | |
| HK1203944A1 (zh) | 用於治療和預防乙型肝炎病毒感染的 -甲基-二氫嘧啶類 | |
| ZA201405820B (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| HK1210463A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| ZA201407866B (en) | Composition for the prevention and treatment of viral infections caused by retroviruses | |
| AU2012900286A0 (en) | "Methods of treatment or prophylaxis" |